1
|
Hou H, Li Y, Tang W, Gao D, Liu Z, Zhao F, Gao X, Ling P, Wang F, Sun F, Tan H. Chondroitin sulfate-based universal nanoparticle delivers angiogenic inhibitor and paclitaxel to exhibit a combination of chemotherapy and anti-angiogenic therapy. Int J Biol Macromol 2024; 271:132520. [PMID: 38772463 DOI: 10.1016/j.ijbiomac.2024.132520] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/13/2024] [Revised: 04/23/2024] [Accepted: 05/17/2024] [Indexed: 05/23/2024]
Abstract
Blocking the tumor nutrient supply through angiogenic inhibitors is an effective treatment approach for malignant tumors. However, using angiogenic inhibitors alone may not be enough to achieve a significant tumor response. Therefore, we recently designed a universal drug delivery system combining chemotherapy and anti-angiogenic therapy to target tumor cells while minimizing drug-related side effects. This system (termed as PCCE) is composed of biomaterial chondroitin sulfate (CS), the anti-angiogenic peptide ES2, and paclitaxel (PTX), which collectively enhance antitumor properties. Interestingly, the PCCE system is conferred exceptional cell membrane permeability due to inherent characteristics of CS, including CD44 receptor-mediated endocytosis. The PCCE could respond to the acidic and high glutathione conditions, thereby releasing PTX and ES2. PCCE could effectively inhibit the proliferation, migration, and invasion of tumor cells and cause apoptosis, while PCCE can affect the endothelial cells tube formation and exert anti-angiogenic function. Consistently, more potent in vivo antitumor efficacy and non-toxic sides were demonstrated in B16F10 xenograft mouse models. PCCE can achieve excellent antitumor activity via modulating angiogenic and apoptosis-related factors. In summary, we have successfully developed an intelligent and responsive CS-based nanocarrier known as PCCE for delivering various antitumor drugs, offering a promising strategy for treating malignant tumors.
Collapse
Affiliation(s)
- Huiwen Hou
- National Glycoengineering Research Center, Shandong University, Qingdao 266237, Shandong, China; NMPA Key Laboratory for Quality Research and Evaluation of Carbohydrate-Based Medicine, Shandong University, Qingdao 266237, China; Shandong Provincial Technology Innovation Center of Carbohydrate, Shandong University, Qingdao 266237, China
| | - Yan Li
- National Glycoengineering Research Center, Shandong University, Qingdao 266237, Shandong, China; NMPA Key Laboratory for Quality Research and Evaluation of Carbohydrate-Based Medicine, Shandong University, Qingdao 266237, China; Shandong Provincial Technology Innovation Center of Carbohydrate, Shandong University, Qingdao 266237, China
| | - Wen Tang
- National Glycoengineering Research Center, Shandong University, Qingdao 266237, Shandong, China; NMPA Key Laboratory for Quality Research and Evaluation of Carbohydrate-Based Medicine, Shandong University, Qingdao 266237, China; Shandong Provincial Technology Innovation Center of Carbohydrate, Shandong University, Qingdao 266237, China
| | - Didi Gao
- National Glycoengineering Research Center, Shandong University, Qingdao 266237, Shandong, China; NMPA Key Laboratory for Quality Research and Evaluation of Carbohydrate-Based Medicine, Shandong University, Qingdao 266237, China; Shandong Provincial Technology Innovation Center of Carbohydrate, Shandong University, Qingdao 266237, China
| | - Zengmei Liu
- National Glycoengineering Research Center, Shandong University, Qingdao 266237, Shandong, China; NMPA Key Laboratory for Quality Research and Evaluation of Carbohydrate-Based Medicine, Shandong University, Qingdao 266237, China; Shandong Provincial Technology Innovation Center of Carbohydrate, Shandong University, Qingdao 266237, China
| | - Feiyan Zhao
- National Glycoengineering Research Center, Shandong University, Qingdao 266237, Shandong, China; NMPA Key Laboratory for Quality Research and Evaluation of Carbohydrate-Based Medicine, Shandong University, Qingdao 266237, China; Shandong Provincial Technology Innovation Center of Carbohydrate, Shandong University, Qingdao 266237, China
| | - Xinqing Gao
- National Glycoengineering Research Center, Shandong University, Qingdao 266237, Shandong, China; NMPA Key Laboratory for Quality Research and Evaluation of Carbohydrate-Based Medicine, Shandong University, Qingdao 266237, China; Shandong Provincial Technology Innovation Center of Carbohydrate, Shandong University, Qingdao 266237, China
| | - Peixue Ling
- National Glycoengineering Research Center, Shandong University, Qingdao 266237, Shandong, China; NMPA Key Laboratory for Quality Research and Evaluation of Carbohydrate-Based Medicine, Shandong University, Qingdao 266237, China; Shandong Provincial Technology Innovation Center of Carbohydrate, Shandong University, Qingdao 266237, China; School of Pharmaceutical sciences, Shandong University, Jinan 250012, China
| | - Fengshan Wang
- National Glycoengineering Research Center, Shandong University, Qingdao 266237, Shandong, China; NMPA Key Laboratory for Quality Research and Evaluation of Carbohydrate-Based Medicine, Shandong University, Qingdao 266237, China; Shandong Provincial Technology Innovation Center of Carbohydrate, Shandong University, Qingdao 266237, China; School of Pharmaceutical sciences, Shandong University, Jinan 250012, China
| | - Feng Sun
- National Glycoengineering Research Center, Shandong University, Qingdao 266237, Shandong, China; NMPA Key Laboratory for Quality Research and Evaluation of Carbohydrate-Based Medicine, Shandong University, Qingdao 266237, China; Shandong Provincial Technology Innovation Center of Carbohydrate, Shandong University, Qingdao 266237, China.
| | - Haining Tan
- National Glycoengineering Research Center, Shandong University, Qingdao 266237, Shandong, China; NMPA Key Laboratory for Quality Research and Evaluation of Carbohydrate-Based Medicine, Shandong University, Qingdao 266237, China; Shandong Provincial Technology Innovation Center of Carbohydrate, Shandong University, Qingdao 266237, China; School of Pharmaceutical sciences, Shandong University, Jinan 250012, China.
| |
Collapse
|
2
|
Yang Q, Li S, Zhou Z, Yang X, Liu Y, Hao K, Fu M. Trimetazidine mitigates high glucose-induced retinal endothelial dysfunction by inhibiting PI3K/Akt/mTOR pathway-mediated autophagy. Bioengineered 2022; 13:7515-7527. [PMID: 35259050 PMCID: PMC8974130 DOI: 10.1080/21655979.2022.2048993] [Citation(s) in RCA: 9] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022] Open
Abstract
Trimetazidine (TMZ), as a metabolic regulator, has been widely testified to exhibit positive therapeutic effects on various disease models, but its role in diabetic retinopathy has not been reported. Therefore, this study was designed with the purpose of exploring the effects of TMZ on high-glucose (HG)-induced retinal endothelial dysfunction and its underlying mechanism. To establish DR model in vitro, 30 mM glucose was applied to induce human retinal endothelial cells (HRECs). Cell proliferation, invasion, and migration were examined by means of Cell Counting Kit-8, transwell, and wound healing assays, respectively. The tubule formation experiment was used to test the tubulogenesis ability and fluorescein isothiocyanate (FITC)-albumin was utilized to measure the permeability of monolayer HRECs. In addition, immunofluorescence and Western blot were employed to detect protein expression. Compared with the HG-induced group, TMZ concentration dependently inhibited the proliferation, migration, and angiogenesis of HG-induced HRECs, decreased the permeability of monolayer HRECs, and increased the protein expression levels of Claudin-5 and VE-cadherin. In addition, TMZ intervention increased the expression of p-PI3K, p-AKT, and p-mTOR but decreased the expression of LC3I, LC3II, and Beclin 1, which were then partially reversed by P13 K inhibitor (LY294002). Moreover, the autophagy agonist rapamycin (RAPA) was also testified to reverse the inhibitory effects of TMZ on the proliferation, migration, and angiogenesis of HG-induced HRECs. In summary, TMZ inhibited excessive autophagy by activating PI3K/Akt/mTOR pathway, thereby improving retinal endothelial dysfunction induced by HG.
Collapse
Affiliation(s)
- Qingsong Yang
- Nanjing Tongren Eye Center, Nanjing Tongren Hospital, School of Medicine Southeast University, Nanjing, P.R. China
| | - Sizhen Li
- Nanjing Tongren Eye Center, Nanjing Tongren Hospital, School of Medicine Southeast University, Nanjing, P.R. China
| | - Zixiu Zhou
- Nanjing Tongren Eye Center, Nanjing Tongren Hospital, School of Medicine Southeast University, Nanjing, P.R. China
| | - Xiaodong Yang
- Nanjing Tongren Eye Center, Nanjing Tongren Hospital, School of Medicine Southeast University, Nanjing, P.R. China
| | - Yating Liu
- Nanjing Tongren Eye Center, Nanjing Tongren Hospital, School of Medicine Southeast University, Nanjing, P.R. China
| | - Kuanxiao Hao
- Nanjing Tongren Eye Center, Nanjing Tongren Hospital, School of Medicine Southeast University, Nanjing, P.R. China
| | - Min Fu
- Nanjing Tongren Eye Center, Nanjing Tongren Hospital, School of Medicine Southeast University, Nanjing, P.R. China
| |
Collapse
|